

RECEIVED
CENTRAL FAX CENTER

MAY 31 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/088,852
	Filing Date	March 21, 2002
	First Named Inventor	Andrew Austen Mortlock
	Art Unit	1624
	Examiner Name	Tamthorn Ngo Truong
	Attorney Docket Number	Z70600-1P US
Total Number of Pages in This Submission		31

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input checked="" type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input checked="" type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AstraZeneca		
Signature			
Printed name	Lucy Clare Padget		
Date	MAY 31, 2005	Reg. No.	Limited Recognition Under 37 CFR § 11.9(b)

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Lucy Clare Padget	Date	May 31, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



RECEIVED
CENTRAL FAX CENTER
MAY 31 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/088852	Applicant: Mortlock et al
371 Filing Date: 03/21/2002	Attorney Docket No.: Z70600 US-1P
Examiner: Tamthom N. Truong	Group Art Unit : 1624
Customer No.: 44992	Confirmation No.: 2243
Title: Quinazoline Derivatives	

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on 31 May 2005

A handwritten signature in black ink, appearing to read "Lucy Padget", written over a horizontal line.

Signature
Lucy Padget

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: AMENDMENT AFTER FINAL

Sirs,

Further to a telephone conversation in the afternoon of May 31, 2005 between Examiner Truong and AstraZeneca Patent Agent, Lucy Padget, in relation to the above identified application, Applicants enclose the following documents:

- a copy of the After Final Response dated January 21, 2005 sent to the USPTO from our attorneys Ropes and Grey, who were at that time handling the case;
- a copy of the USPTO stamped return receipt postcard, stamped January 24, 2005;
- a notice of appeal; and
- a petition for extension of time.

From the above documentation it appears that the USPTO did receive the after final response from our agents on January 24th, 2005.


Six months from the date of mailing the final rejection expire on June 3rd, 2005 thus Applicants enclose a notice of appeal with this letter to ensure the application remains pending.

Application No. 10/088852
Amendment Dated 12/03/2004
Reply to Office Action of 05/31/2005

Applicants initially responded within two months from the date of mailing the final rejection and never received an advisory action. Therefore Applicants do not believe a petition for extension of time is necessary. However, should the USPTO consider that this is necessary, the USPTO may consider this letter the petition for the necessary extension of time and Applicants attach Form PTO/SB/22 with an authorization to charge any fees which may be due to our deposit account.

The Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. Z70600 US-1.

Respectfully submitted,



Name: Lucy Padget
Dated: 05/31/2005
Reg. No.: Limited Recognition
Phone No.: 781-839-4182

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 01760

Enclosures: Transmittal Form
Copy of the After Final Response dated January 21, 2005
Copy of the USPTO stamped return receipt postcard, stamped January 24, 2005
Notice of appeal
Petition of extension of time
Limited Recognition

Via: First Class Mail	
Inventor: Mortlock et al.	Atty Dkt No.: ASZD-P01-600
Application No.: 10/088852	Filing Date: March 21, 2002
Title: QUINAZOLINE DERIVATIVES	

Documents Filed:
Amendment Transmittal (1 page)
Reply Under 37 CFR 1.111 (21 pages)
Return receipt postcard

Sender's Initials: DPH/amb	Date: January 21, 2005
----------------------------	------------------------

9635194.1

Via: First Class Mail	
Inventor: Mortlock et al.	Atty Dkt No.: ASZD-P01-600
Application No.: 10/088852	Filing Date: March 21, 2002
Title: QUINAZOLINE DERIVATIVES	

Documents Filed:
Amendment Transmittal (1 page)
Reply Under 37 CFR 1.111 (21 pages)
Return receipt postcard





Ropes & Gray

JAN 28 2005

Sender's Initials: DPH/amb	Date: January 21, 2005
----------------------------	------------------------

Intellectual Property Dept.

9635194.1

AMENDMENT TRANSMITTAL LETTER				Docket No. ASZD-P01-600	
Application No. 10/088852		Filing Date March 21, 2002		Examiner T. N. Truong	
				Art Unit 1624	
Applicant(s): Mortlock et al.					
Invention: QUINAZOLINE DERIVATIVES					
TO THE COMMISSIONER FOR PATENTS					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	42	- 42 =	0	x	
Independent Claims	6	- 6 =	0	x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00
<input checked="" type="checkbox"/> Large Entity <input type="checkbox"/> Small Entity					
<input checked="" type="checkbox"/> No additional fee is required for this amendment.					
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of \$ _____. A duplicate copy of this sheet is enclosed.					
<input type="checkbox"/> A check in the amount of \$ _____ to cover the filing fee is enclosed.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>18-1945</u> as described below. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> Credit any overpayment.					
<input checked="" type="checkbox"/> Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.					
 David P. Halstead Attorney Reg. No.: 44,735 ROPES & GRAY LLP One International Place Boston, Massachusetts 02110-2624 (617) 951-7449				Dated: <u>January 21, 2005</u>	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.					
Dated: <u>1/21/05</u>		Signature:  (Andrea Berlo)			


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Ms. Lucy Clare Padget is hereby given limited recognition under 37 CFR §11.9(b) as an employee of AstraZeneca Pharmaceuticals, LP to prepare and prosecute patent applications wherein the assignee of record is AstraZeneca Pharmaceuticals, LP, and the attorney or agent of record in the applications is a registered practitioner who is an employee of AstraZeneca Pharmaceuticals, LP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Ms. Lucy Clare Padget ceases to lawfully reside in the United States, (ii) Ms. Lucy Clare Padget's employment with AstraZeneca Pharmaceuticals, LP ceases or is terminated, or (iii) Ms. Lucy Clare Padget ceases to remain or reside in the United States on an E-2 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: March 18, 2006



Harry I. Moatz

Director of Enrollment and Discipline